Journal ArticleDOI
Bevacizumab as salvage therapy for progressive brain stem gliomas.
Thomas Reithmeier,W.O. Contreras Lopez,Timo S. Spehl,T. Nguyen,Irina Mader,Guido Nikkhah,Marcus O. Pinsker +6 more
TLDR
Treatment of progressive gliomas involving the brain stem with bevacizumab resulted in an improved clinical condition of the patients as well as a reduction of the T2 weighted lesions and reduced amino acid uptake in the tumor area, which may represent a therapeutic salvage option for this type of tumor.About:
This article is published in Clinical Neurology and Neurosurgery.The article was published on 2013-02-01. It has received 20 citations till now. The article focuses on the topics: Anaplastic astrocytoma & Salvage therapy.read more
Citations
More filters
Journal ArticleDOI
From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?
TL;DR: In the last decade, PET studies using radiolabeled amino acids appear to improve clinical decision-making as these tracers can offer better delineation of tumor extent as well as improved targeting of biopsies, surgical interventions, and radiation therapy.
Journal ArticleDOI
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.
TL;DR: This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[ 18F]-fluoro- l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.
Journal ArticleDOI
Current status of PET imaging in neuro-oncology.
Norbert Galldiks,Norbert Galldiks,Philipp Lohmann,Nathalie L. Albert,Jörg C. Tonn,Karl-Josef Langen +5 more
TL;DR: The value of PET imaging for the latter-mentioned 3 clinically relevant indications in patients with glioma, meningiomas, and brain metastases is summarized.
Journal ArticleDOI
Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.
TL;DR: The authors review the results of important clinical trials/studies, the current understanding of the mechanisms of action and resistance, and the knowledge of imaging characteristics and biomarkers predicting the response to Bev to improve the overall clinical outcome and optimize individual therapy.
Journal ArticleDOI
Adult brainstem gliomas: Correlation of clinical and molecular features.
Brett Theeler,Benjamin Ellezam,Isaac Melguizo-Gavilanes,John de Groot,Anita Mahajan,Kenneth Aldape,Janet M. Bruner,Vinay K. Puduvalli +7 more
TL;DR: Survival outcomes for adult WHO Grade II to IV brainstem gliomas were similar to supratentorial IDH1 wild-type tumors of similar grade and histology, and potentially actionable mutations can be identified from small biopsy samples in a subset of adult brainstemgliomas.
References
More filters
Journal ArticleDOI
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen,David R. Macdonald,David A. Reardon,Timothy F. Cloughesy,A. Gregory Sorensen,Evanthia Galanis,John DeGroot,Wolfgang Wick,Mark R. Gilbert,Andrew B. Lassman,Christina Tsien,Tom Mikkelsen,Eric T. Wong,Marc C. Chamberlain,Roger Stupp,Kathleen R. Lamborn,Michael A. Vogelbaum,Martin J. van den Bent,Susan M. Chang +18 more
TL;DR: The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
Journal ArticleDOI
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl,Lyndon Kim,Kraig Moore,Paul Duic,Cheryl Royce,Irene Stroud,Nancy Garren,Megan Mackey,John A. Butman,Kevin Camphausen,John W. Park,Paul S. Albert,Howard A. Fine +12 more
TL;DR: It is concluded that single-agent bevacizumab has significant biologic and antiglioma activity in patients with recurrent glioblastoma.
Journal ArticleDOI
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Andrew D. Norden,Geoffrey S. Young,Kian Setayesh,Alona Muzikansky,Roman A. Klufas,G. L. Ross,A. S. Ciampa,L. G. Ebbeling,Brenda Levy,Jan Drappatz,Santosh Kesari,Patrick Y. Wen +11 more
TL;DR: Combination therapy with bevacizumab and chemotherapy is well-tolerated and active against recurrent malignant gliomas and may alter the recurrence pattern of malignantgliomas by suppressing enhancing tumor recurrence more effectively than it suppresses nonenhancing, infiltrative tumor growth.
Journal ArticleDOI
FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading
Gabriele Pöpperl,Friedrich W. Kreth,Jan H. Mehrkens,Jochen Herms,Klaus Seelos,Walter Koch,Franz Josef Gildehaus,Hans A. Kretzschmar,Jörg C. Tonn,Klaus Tatsch +9 more
TL;DR: Based on the ratio-based method, a statistically significant difference was found between LG and HG gliomas and should supplement the conventional method.
Journal ArticleDOI
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Ashwatha Narayana,Patrick J. Kelly,John G. Golfinos,Erik C. Parker,Glyn Johnson,Edmond A. Knopp,David Zagzag,Ingeborg Fischer,Shahzad Raza,Praveen Medabalmi,Patricia Eagan,Patricia Eagan,Michael L. Gruber,Michael L. Gruber +13 more
TL;DR: Antiangiogenic therapy using bevacizumab appears to improve survival in patients with recurrent high-grade glioma, and a possible change in the invasiveness of the tumor following therapy is worrisome and must be closely monitored.
Related Papers (5)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen,David R. Macdonald,David A. Reardon,Timothy F. Cloughesy,A. Gregory Sorensen,Evanthia Galanis,John DeGroot,Wolfgang Wick,Mark R. Gilbert,Andrew B. Lassman,Christina Tsien,Tom Mikkelsen,Eric T. Wong,Marc C. Chamberlain,Roger Stupp,Kathleen R. Lamborn,Michael A. Vogelbaum,Martin J. van den Bent,Susan M. Chang +18 more
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET
Norbert Galldiks,Veronika Dunkl,Veronika Dunkl,Gabriele Stoffels,Markus Hutterer,Marion Rapp,Michael Sabel,Guido Reifenberger,Sied Kebir,Franziska Dorn,Tobias Blau,Ulrich Herrlinger,Ulrich Herrlinger,Peter Hau,Maximilian I. Ruge,Martin Kocher,Roland Goldbrunner,Gereon R. Fink,Gereon R. Fink,Alexander Drzezga,Matthias Schmidt,Karl-Josef Langen,Karl-Josef Langen +22 more